Rimonabant: A novel approach for the treatment of obesity and cardiometabolic risk by blockade of the endocannabinoid system

Future Cardiology

Volumn 3, Issue 5, 2007, Pages 497-505

  Colleran, Kathleen ^a   Pai, Hemanth ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Cardiometabolic risk; Endocannabinoid receptor blocker; Endocannabinoid system; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE DERIVATIVE; CANNABINOID 1 RECEPTOR; DIGOXIN; ENDOCANNABINOID; ETHINYLESTRADIOL; EXENDIN 4; INCRETIN; KETOCONAZOLE; LEVONORGESTREL; METFORMIN; MIDAZOLAM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; RIMONABANT; SITAGLIPTIN; SULFONYLUREA; WARFARIN;

ABDOMINAL OBESITY; ANGER; ANXIETY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG MECHANISM; DYSPHORIA; EMOTIONAL DISORDER; EPIDEMIC; FALLING; FATIGUE; FOOD INTAKE; GLUCOSE HOMEOSTASIS; HALLUCINATION; HEADACHE; HICCUP; HOT FLUSH; HUMAN; HUNGER; HYPERHIDROSIS; INFLUENZA; INSOMNIA; INSULIN RESISTANCE; IRRITABILITY; LETHARGY; LIPID METABOLISM; LIPOGENESIS; MAJOR DEPRESSION; MENTAL DISEASE; METABOLIC SYNDROME X; MONOTHERAPY; MOOD CHANGE; MOOD DISORDER; MOTOR DYSFUNCTION; MUSCLE CRAMP; MUSCLE SPASM; NAUSEA; NERVOUSNESS; NEUROLOGIC DISEASE; NIGHT SWEAT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANIC; PARASOMNIA; PARESTHESIA; PRIORITY JOURNAL; RECEPTOR BLOCKING; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SATIETY; SIDE EFFECT; SINUSITIS; SLEEP DISORDER; SPRAIN; STRESS; TENDINITIS; VERTIGO; VIRAL GASTROENTERITIS; WEIGHT REDUCTION;

EID: 34648824851     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.3.5.497     Document Type: Article

References (35)

1. Ogden CL, Carroll MD, Flegal KM: Epidemiologic trends in overweight and obesity. Endocrin. Metabol. Clin. North Am. 32(4), 741-760 (2003).
2. 2) for the United States, England and Wales, Mauritius, Australia and Brazil firom 1960 to 2025. Nature 404, 635-643 (2000).
3. Mokdad AH, Ford ES, Bowman BA et al.: Prevalence of obesity, diabetes, and obcsity-related health risk factors, 2001. JAMA 289, 76-79 (2003).
4. Gupta M, Singh N, Verma S: South Asians and cardiovascular risk: what clinicians should know. Circulation 113, e924-e929 (2006).
5. Burke JP, Williams K, Gaskill SP et al.: Rapid rise in the incidence of Type 2 diabetes from 1987 to 1996. Arch. Intern. Med. 159, 1450-1456 (1999).
6. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21, 1414-1431 (1998).
7. Alexander CN, Landsman PB, Teutsch SM, Hafner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52, 1210-1214 (2003).
8. Isomaa B, Almgren P, Tuomi T et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24, 683-689 (2001).
9. Expert panel on detection, evaluation and treatment of high blood cholesterol: Executive Summary of the third report of the National Cholesterol and Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
10. Blaha M, Elasy TA: Clinical use of the metabolic syndrome: why the confusion? Clin. Diabetes 24, 125-131 (2006).
11. Basu A, Jensen M, McCann F et al.: Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in Type 2 diabetes. Diabetes Care 29, 510-514 (2006).
12. Dormandy JA, Charbonnel B, Eckland DJ et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (Propsective pioglitazone clinical trial in macrovascular events): a randomized controlled trial. Lancet 366, 1279-89 (2005).
13. UKPD Study group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352, 837-853 (1998).
14. Blonde L, Klien EJ, Han J et al.: Interim analysis of the effects of exenatide treatment on A1C weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with Type 2 diabetes. Diabetes Obes. Metab. 8, 436-447 (2006).
15. Collins R, Armitage J, Parish S, Sleigh P, Peto R: Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361, 2005-2016 (2003).
16. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000).
17. Dahlöf B, Devereux RB, Kjeldsen SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 995-1003 (2002).
18. Devane WA, Hanus L, Breuer A et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949 (1992).
19. Matsuda LA: Molecular aspects of cannabinoid receptors. Crit. Rev. Neurobiol. 11, 143-166 (1997).
20. Di Matzo V, Melck D, Bisogno T, De Petrocellis L: Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21, 521-528 (1998).
21. Cora D, Marsicano G, Tschöp M et al.: The endogenous cannabinoid-system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112, 423-431 (2003).
22. Di Marzo V, Matias I: Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 8, 585-589 (2005).
23. Gomez RG, Navarro M, Ferrer B et al.: A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J. Neurosci. 2, 9612-9617 (2002).
24. Kirkham TC, Williams CM, Fezza F, Di Marzo V: Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonyl glycerol. Br. J. Pharmacol. 136, 550-557 (2002).
25. Wilson RI, Nicholl RA: Endocannabinoid signaling in the brain. Science 296, 678-682 (2002).
26. Galiegue S, Mary S, Marchand J et al.: Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232, 54-61 (1995).
27. Rinaldi-Carmona M, Barth F, Heaulme M et al. Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56, 1941-1947 (1995).
28. Liu YL, Connoley IP, Wilson CA, Stock, MJ: Effect of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep (ob)/Lep (ob) mice. Int. J. Obes. (London) 29, 183-187 (2005).
29. Bensaid M, Gary-Bobo M, Esclangon A et al.: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 63, 908-914 (2003).
30. Pagotto U, Vicennati V, Pasquali R: The endocannabinoid syttem and the teatment of obesity. Ann. Med. 37, 270-275 (2005).
31. Jensen M, Abu-Lebdeh H, Geohas J et al.: The selective CB1-receptor antagonist rimonabant reduces body weight and waist circumferene in obese subjects. Int. J. Obes. 28, S27 (2004).
32. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America Study Group. JAMA 295, 761-775 (2006).
33. Van Gaal LF, Rissanen AM, Schoen AJ, Ziegler O, Rossner S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experiencefrom the RIO-Europe study. RIO-Europe Study Group. Lancet 365, 1389-1397 (2005).
34. Després JP, Golay A, Sjöström L et al.: Effects of rimonabant on metabolic risk factors in overweight patients with dislipidemia. N. Engl. J. Med. 353, 2121-2134 (2005).
35. Scheen A, Finer N, Hollander P, Jensen MD, Van Gaal L: Efficacy and tolerability of rimonabant in overweigh or obese patients with Type 2 diabetes; a randomized controlled study. RIO-Diabetes Study Group. Lancet 368, 1660-1672 (2006).